PR Newswire BiotechOriginal article
GeneChem Inc. Receives U.S. FDA NDIN No Objection for Siallac6®, 6'-Sialyllactose Sodium Salt in Collaboration with REJIMUS, INC.
RegulatoryapprovedSiallac6®Positive
AI Analysis
Summary
GeneChem Inc. received FDA No Objection for its NDIN submission for Siallac6® (6'-Sialyllactose Sodium Salt) in collaboration with REJIMUS, INC., enabling regulatory pathway progression for the high-value biomaterial.
Outcome Details
FDA issued NDIN (New Dietary Ingredient Notification) No Objection letter
Importance:7/10
Sentiment:
0.80
FDA approvalregulatory clearancebiomaterialsenzyme engineeringNDINcollaboration
Read the original article
Published by PR Newswire Biotech on August 7, 2026 3:00 PM